Rhythm Biosciences Ltd. (RHY) Share Price & Analysis

13 Followers

RHY Stock Chart & Stats

A$0.07A$0.00(1.54%)

At close: Nov 12 4:00 PM GMT+11

Day’s Range: AUD 0.06 - AUD 0.07
52-Week Range: AUD 0.06 - AUD 0.28
Previous Close: AUD 0.07
Volume: N/A
Average Volume (3M): 128.52K
Market Cap: AUD 23.66M
Enterprise Value: AUD 28.21M
Total Cash (Recent Filing): AUD 3.44M
Total Debt (Recent Filing): AUD 247.98K
Price to Earnings (P/E): ―
Beta: 0.93
Next Earnings: Feb 24, 2027 (Est.)
EPS Estimate: N/A
Next Dividend Ex-Date: N/A
Dividend Yield: N/A

Bulls Say, Bears Say

Bulls Say

Manageable Leverage

Low debt and positive equity provide a comparatively flexible financial base for a small diagnostics company. This can reduce near-term balance-sheet strain and preserve some capacity to support product development, although ongoing losses could erode that flexibility if performance does not improve.

Focused Diagnostic Pipeline

A defined focus on in-vitro diagnostics and colorectal cancer screening gives the business a clear product-development direction. ColoSTAT provides a specific commercial objective, while related diagnostic activities could support longer-term opportunities if development and commercialisation progress successfully.

Demonstrated Revenue Capacity

Revenue reaching approximately 3.19M in FY2025 shows the company has demonstrated an ability to generate meaningful revenue in some periods. That history provides evidence of commercial potential, even though converting revenue into consistent profitability remains unresolved.

Bears Say

Persistent Losses

Persistent losses indicate that the current business model has not yet reached sustainable profitability. Continued negative EBIT and EBITDA reduce internal funding capacity, may pressure the equity base over time, and leave future progress dependent on successful commercial execution or additional financing.

Volatile Revenue And Margins

The sharp annual revenue decline and materially negative gross profit show that commercial activity is currently unstable and operating leverage is unfavorable at low scale. Such volatility makes forward planning more difficult and suggests the company has not yet established a dependable revenue base or sustainable margin structure.

Persistent Cash Burn

Sizable negative operating and free cash flow mean the company is consuming cash rather than funding operations internally. If this pattern persists, reserves or external capital will be needed to sustain development, increasing funding dependence and potentially limiting strategic flexibility over the next several quarters.

Rhythm Biosciences Ltd. News

ColoSTAT Reaches 95% of Australian GP Practices

Rhythm Biosciences Ltd. ( ($AU:RHY) ) just unveiled an update. Rhythm Biosciences is an Australian medical diagnostics company focused on simple, affordable blood tests for early cancer detection, with ColoSTAT,

1w agoRHY

Rhythm Biosciences Release Provides No Substantive Operational Update

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an update. Rhythm Biosciences Ltd. is an ASX-listed life sciences company; the material provided does not specify its products, services or market

1w agoRHY

Rhythm Biosciences advances ColoSTAT rollout and broadens cancer diagnostics portfolio

Rhythm Biosciences Ltd. ( ($AU:RHY) ) just unveiled an announcement. Rhythm Biosciences has accelerated the commercial rollout of its ColoSTAT® colorectal cancer test in Australia by integrating ordering into MedicalDirector

2w agoRHY

Rhythm Biosciences Sets Details for 2026 Hybrid Annual General Meeting

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has provided an announcement. Rhythm Biosciences Limited has called its 2026 Annual General Meeting for 11:00 a.m. AEDT on Tuesday, 24 November 2026, to

2w agoRHY

Rhythm Biosciences Study Flags Major Cost Savings from ColoSTAT in Public Hospitals

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an announcement. Rhythm Biosciences has reported results from an independent health economic study indicating that ColoSTAT, when used by GPs to triage

1M agoRHY

Rhythm Biosciences Files Updated Corporate Governance Statement With ASX

An announcement from Rhythm Biosciences Ltd. ( ($AU:RHY) ) is now available. Rhythm Biosciences Ltd., an Australian biotechnology company, operates under the ASX listing framework with a focus on transparent

1M agoRHY

Rhythm Biosciences Sets Date for 2026 AGM and Director Nomination Deadline

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences has scheduled its 2026 Annual General Meeting for 24 November in Melbourne, in line with ASX listing requirements.

1M agoRHY

Rhythm Biosciences Names Interim Chair as Board Reshuffles During Commercialisation Push

The latest announcement is out from Rhythm Biosciences Ltd. ( ($AU:RHY) ). Rhythm Biosciences has announced that Chair and Non-Executive Director Gavin Fox-Smith has resigned from the board with immediate

1M agoRHY

Rhythm Biosciences Advances ColoSTAT NHS Assessment With Key Technology Transfer Milestone

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has shared an announcement. Rhythm Biosciences has announced that the Southern Hub research team at the Royal Surrey NHS Foundation Trust in England has

1M agoRHY

Rhythm Biosciences Adds Independent Director Maureen Baker to Board

Rhythm Biosciences Ltd. ( ($AU:RHY) ) has issued an announcement. Rhythm Biosciences Limited has announced the appointment of Maureen Baker as a director effective 27 August 2026, expanding the company’s

2M agoRHY

RHY FAQ

What was Rhythm Biosciences Ltd.’s price range in the past 12 months?

Rhythm Biosciences Ltd. lowest share price was AU$0.06 and its highest was AU$0.28 in the past 12 months.

What is Rhythm Biosciences Ltd.’s market cap?

Rhythm Biosciences Ltd.’s market cap is AU$23.66M.

When is Rhythm Biosciences Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Rhythm Biosciences Ltd.’s earnings last quarter?

Rhythm Biosciences Ltd. released its earnings results on Aug 27, 2026. The company reported -AU$0.011 earnings per share for the quarter.

Is Rhythm Biosciences Ltd. overvalued?

Not enough analysts have published a price target to calculate whether the price is overvalued.

Does Rhythm Biosciences Ltd. pay dividends?

Rhythm Biosciences Ltd. does not currently pay dividends.

What is Rhythm Biosciences Ltd.’s EPS estimate?

Rhythm Biosciences Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Rhythm Biosciences Ltd. have?

Rhythm Biosciences Ltd. has 364,059,840 shares outstanding.

What happened to Rhythm Biosciences Ltd.’s price movement after its last earnings report?

Rhythm Biosciences Ltd. reported an EPS of -AU$0.011 in its last earnings report. Following the earnings report the stock price went down -1.01%.

Which hedge fund is a major shareholder of Rhythm Biosciences Ltd.?

Currently, no hedge funds are holding shares in AU:RHY

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Rhythm Biosciences Ltd. Stock Smart Score

Underperform

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description